Weight Management and GLP-1

Where the shrinkage actually sits

Weight management is the only one of Herbalife's three largest product lines smaller today than it was in 2019, and the company's own named competitors show why. Protein sold at retail grew about 40% over the two years to 2025; the diet-branded version of the same shelf fell 20%; every direct seller in the set fell further than Herbalife. The evidence does not support GLP-1 drugs shrinking nutrition demand. It supports them shrinking the diet-branded, coach-mediated form of it.

Sources: Herbalife FY2025 Form 10-K, segment note [1] and FY2021 Form 10-K, segment note [2]; BellRing Brands FY2025 Form 10-K, disaggregated net sales [3]; Medifast FY2025 Form 10-K [4] and FY2024 Form 10-K [5].

Herbalife reports net sales in five product lines. Across the seven years from 2019 to 2025 the company as a whole grew 3.3%, from $4,877.1 million to $5,037.5 million [6] [7]. Inside that flat total, the lines moved in opposite directions. Energy, sports and fitness rose 75.3%, from $352.0 million to $617.1 million. Targeted nutrition rose 18.1%, from $1,278.5 million to $1,509.6 million. Weight management fell 8.8%, from $3,012.5 million to $2,746.7 million — and it is the line that carries 54.5% of net sales, down from 61.8% in 2019 [8] [9].

Source: derived from reported net sales by product line, FY2021 Form 10-K [10] and FY2025 Form 10-K [11]; FY2022 figures from the FY2023 Form 10-K segment note [12].

The picture is not a company in decline with one bright spot. It is a company whose non-weight-management business has grown steadily through the whole period, offset by erosion in the line that defines it. Formula 1, the meal-replacement shake, still accounted for 25% of net sales in 2025, down from 27% in 2021 [13] [14]. Management has begun describing the destination in the same terms: the CEO opened the Q2 2025 call by saying Herbalife is "in motion from our roots as a weight management company to becoming the number one active and lifestyle nutrition brand in the world" [15].

What the filings say about the drugs

Across five annual reports covering 2021 through 2025 — the entire period in which semaglutide moved from a diabetes drug to a mass-market weight-loss product — the term GLP-1 does not appear once in Herbalife's Form 10-K. The competition risk factor does refer to "various prescription drugs, which may rapidly capture a significant share of the market," but that sentence has stood word-for-word in the risk factors since the FY2021 filing [16] [17]. It is pre-existing boilerplate, not an acknowledgment.

The earnings calls do mention the drugs, on a count that rises and then falls back to zero. GLP-1 is mentioned zero times in every call from Q2 2021 through Q1 2023. It appears five times in the Q2 2023 call, where management said the drugs were "getting a lot of headlines" and that "we are watching this trend closely" [18], and twice more in Q3 2023. It peaks at ten mentions in each of the Q4 2023 and Q1 2024 calls; on the Q4 2023 call management ruled out competing directly: "We don't see ourselves in the near future offering a GLP-1 product. We believe that our strength is in the behavioral modification, giving product to people that complements a GLP-1 user on their journey" [19]. It then decays: nothing on the next two calls, a single passing reference in Q4 2024, nothing again until five mentions in Q3 2025 — the last of those being an analyst asking how the thinking had evolved, answered by pointing at MultiBurn, a non-pharmaceutical weight-loss supplement, as "a natural alternative" for those who prefer not to use the drugs [20]. In the two most recent calls, February and May 2026, neither management nor any analyst raised GLP-1 at all.

What did change in the filings is the competitor list. In FY2021 Herbalife named its non-direct-selling competitors as Conagra Brands, Hain Celestial and Post, and its direct-selling competitors as Nu Skin, Tupperware and USANA [21]. In the FY2023 filing that list was rewritten to add BellRing Brands and The Simply Good Foods Company on the retail side and Medifast and Amway on the direct-selling side [22]. By FY2025, Conagra, Post and Tupperware were gone and Nestlé had been added [23]. Herbalife's own view of who it competes with moved from packaged food to branded protein at retail. That list is also the reason the peer test below is a fair one: these are the companies Herbalife names, not a market-cap screen.

The retail control

BellRing Brands and Simply Good Foods sell the same nutrition to the same consumers through grocery, club, mass and e-commerce instead of through a distributor. Both are exposed to exactly the same GLP-1 penetration in exactly the same country. Their numbers over the two years to fiscal 2025 are inconsistent with a demand shock at the category level.

BellRing's net sales rose from $1,666.8 million in fiscal 2023 to $2,316.6 million in fiscal 2025, up 39.0% [24]. Its shakes line alone — the direct product analogue of Formula 1 — rose from $1,320.2 million to $1,892.9 million, up 43.4% [25].

Simply Good Foods splits the test more finely still, because it runs two brands from one platform. Quest, positioned around protein, grew from $682.8 million to $863.6 million, up 26.5%. Atkins, positioned around weight management and low-carbohydrate dieting, fell from $526.8 million to $420.8 million, down 20.1% [26]. The two brands share shelves, buyers, salesforce and the same drugs in the market, and the spread between the protein framing and the diet framing is nearly 47 percentage points.

Herbalife's weight-management line over the same two calendar years fell 3.7%, from $2,851.7 million to $2,746.7 million [27].

The direct-selling control

The same two years run the other way for the channel.

Sources: Herbalife FY2025 Form 10-K [28]; BellRing FY2025 Form 10-K [29]; Simply Good Foods FY2025 Form 10-K [30]; Nu Skin FY2025 Form 10-K [31]; Medifast FY2025 Form 10-K [32]. Fiscal years differ: BellRing ends September, Simply Good Foods ends August, the others December.

Medifast is the closest structural analogue Herbalife has: a coach-mediated, weight-loss-first, direct-selling nutrition business in the United States. Its revenue fell from $1,598.6 million in 2022 to $1,072.1 million in 2023, $602.5 million in 2024 and $385.8 million in 2025 — a 75.9% decline from the peak [33] [34]. Its distributor equivalent went with it: active earning coaches fell from 27,100 at the end of 2024 to 19,500 in September 2025 and 16,100 at the end of 2025, a series the company says has been declining since the first quarter of 2023 [35].

Medifast is also the peer that tested the partner-with-the-drug strategy in cash. In the fourth quarter of 2023 it bought $10 million of common stock in LifeMD, a virtual primary-care provider, to anchor a telehealth GLP-1 offering [36]. It sold the entire holding in the second quarter of 2025 [37]. Its FY2025 filing now argues the opposite case Herbalife makes on its calls, and in more detail: roughly one-third of GLP-1 users discontinue within six months and up to 74% within a year, and two-thirds of the weight lost is typically regained within twelve months of stopping [38]. Whatever the merit of that argument, it did not stop the decline.

Nu Skin, the other same-model control this report has used (Sales Leader Turnover), fell from $1,969.1 million to $1,485.2 million over the same two years, down 24.6% [39]. Herbalife's total net sales over the same window were essentially unchanged, from $5,062.4 million to $5,037.5 million [40]. Excluding India, the rest of the company fell 2.8% over the same two years, an arithmetic set out in full in India Concentration [41]. Herbalife is the best performer in a contracting channel on the strength of that one market (India Concentration).

The United States, six years on

The United States is where GLP-1 penetration is highest, where retail protein is most available, and where Medifast lost three-quarters of its business. Herbalife's US net sales were $1,002.6 million in 2019, rose to $1,386.7 million in 2021, and were $1,006.4 million in 2025 [42] [43].

Sources: Herbalife FY2021 Form 10-K, segment note [44] and FY2025 Form 10-K, segment note [45]; 2022 from the FY2023 Form 10-K segment note [46].

Six years produced a round trip and no growth, not a collapse: $1,002.6 million in 2019, a peak of $1,386.7 million in 2021, and $1,006.4 million in 2025. That series is consistent with a pandemic bubble unwinding into a stagnant base rather than with the category being taken away. It sits between the retail control, which grew, and Medifast, which lost 76%. The honest reading is that in Herbalife's largest developed market the drugs are one headwind among several rather than the mechanism — and that the network held a base Medifast could not hold.

Two caveats bound that reading. The United States is also the market where the 2016 FTC consent order constrains how volume is recognised — a US Member earns no Volume Points until the product is sold on to a customer at a profit and the sale is documented [47] — so it is not a clean experiment for the channel question either. And Herbalife's own attempt to compete on product has not yet shown up at the country level: MultiBurn launched in North America in July 2025 and management said initial sales were outpacing expectations [48] and that it "significantly contributed to our performance in Q3" [49], yet full-year 2025 US net sales still fell to $1,006.4 million from $1,026.0 million [50].

India, from March 2026

The forward version of this test is not American. On 20 March 2026 the Indian patent on semaglutide expired, and more than forty domestic manufacturers launched generic versions; Natco Pharma priced an injectable at roughly $14 a month, against branded semaglutide at the equivalent of roughly $125 to $190 a month after Novo Nordisk's own pre-expiry price cuts. That is a fresh market fact drawn from press reporting rather than from the filing corpus, and it should be treated as such.

Its relevance is arithmetic. India was $889.6 million of Herbalife's FY2025 net sales, 17.7% of the total [51], a share that rose again in the March 2026 quarter and carried the whole of the company's local-currency growth (India Concentration). The March 2026 quarter closed eleven days after the generics launched, so it contains essentially no exposure. The June 2026 quarter is the first that does.

The comparison should not be overdrawn. India's per-capita income makes even a $14 monthly injectable a different proposition than in the United States, the addressable population for anti-obesity prescriptions there is small relative to Herbalife's customer base, and the American analogue took roughly three years to move Medifast's reported numbers. But the two forces this chapter separates, a drug-driven demand headwind and a channel losing to retail, are both arriving in India, which was 17.7% of FY2025 net sales and carried the whole of the company's local-currency growth, and they arrive alongside the September 2026 GST anniversary.

The read, and what would change it

On the moat question the evidence supports a narrow advantage, and one that is geographically contingent rather than structural. What Herbalife owns is a distributor relationship that keeps customers buying a commodity nutrition product at a price retail undercuts; the value of that relationship is demonstrable where retail protein is thin and prescription weight loss is absent, and thin where they are not. It is not a product advantage: the gap between Quest and Atkins shows the category is being reallocated by brand positioning, not destroyed, and Herbalife's own product line moved the wrong way while its energy-and-fitness line moved the right way. Herbalife's response runs through execution rather than product economics: a faster launch cadence, MultiBurn and Life I/O.

The strongest fact against that read is Herbalife's own resilience relative to its closest structural peer. Its weight-management line fell 3.7% over the two years in which Medifast, running the same model in the same country against the same drugs, lost 64% of its entire business [52] [53]. Something in the network — daily-consumption habit, Nutrition Club community, geographic breadth — holds a base that Medifast's did not.

Two observable things would separate a durable network advantage from a delayed decline. India volume growth holding through 2027 with generic semaglutide freely available would establish that the distributor relationship survives a cheap pharmaceutical substitute, which is the strongest version of the bull case available. India volume rolling over within four quarters of the March 2026 launch, in a company where the rest of the business is already shrinking about 1.5% a year, would settle it the other way. Both are reported quarterly, in the same regional table Herbalife already publishes.